Theravance Biopharma (TBPH) CEO awarded 75,000 Ordinary Shares

Rhea-AI Filing Summary

Theravance Biopharma CEO Rick E. Winningham received an equity grant of 75,000 Ordinary Shares at no cost. The award was recorded as a grant or other acquisition on Ordinary Shares.

Following this grant, he directly holds 1,651,094 Ordinary Shares and also reports indirect holdings of 23,400 shares as custodian and 92,567 shares held by a trust.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Winningham Rick E

Role CHIEF EXECUTIVE OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	75,000	$0.00	--
holding	Ordinary Shares	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Ordinary Shares — 1,651,094 shares (Direct); Ordinary Shares — 23,400 shares (Indirect, As Custodian)

Footnotes (1)

Key Figures

Share grant: 75,000 shares Grant price: $0.00 per share Direct holdings after grant: 1,651,094 shares +2 more

5 metrics

Share grant 75,000 shares Ordinary Shares granted to CEO on 2026-04-01

Grant price $0.00 per share Price for 75,000 Ordinary Shares award

Direct holdings after grant 1,651,094 shares Ordinary Shares directly held by CEO after transaction

Indirect holdings as custodian 23,400 shares Ordinary Shares held indirectly as custodian

Indirect holdings by trust 92,567 shares Ordinary Shares held indirectly by trust

Key Terms

Ordinary Shares, Grant, award, or other acquisition, As Custodian, By Trust

4 terms

Ordinary Shares financial

"security_title: "Ordinary Shares" for each entry"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

As Custodian financial

"nature_of_ownership: "As Custodian""

By Trust financial

"nature_of_ownership: "By Trust""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Winningham Rick E

(Last) (First) (Middle)

C/O THERAVANCE BIOPHARMA US, LLC

901 GATEWAY BOULEVARD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	04/01/2026		A		75,000	A	$0	1,651,094	D
Ordinary Shares								23,400	I	As Custodian
Ordinary Shares								92,567	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Brett A Grimaud, Attorney-in-Fact	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Theravance Biopharma (TBPH) report for its CEO?

Theravance Biopharma reported that CEO Rick E. Winningham received a grant of 75,000 Ordinary Shares at a price of $0.00 per share. This was classified as a grant or award acquisition, typical of equity-based executive compensation.

How many Theravance Biopharma (TBPH) shares does the CEO hold after this grant?

After the grant, CEO Rick E. Winningham directly holds 1,651,094 Ordinary Shares. The Form 4 also shows 23,400 shares held indirectly as custodian and 92,567 shares held indirectly by a trust associated with him.

Was the 75,000-share award to the Theravance (TBPH) CEO a market purchase?

No, the 75,000 Ordinary Shares were reported as a grant, award, or other acquisition with a price of $0.00 per share. This indicates a compensation-related award, not an open-market purchase of Theravance Biopharma stock.

Does the Theravance (TBPH) Form 4 show any insider stock sales by the CEO?

The Form 4 shows no reported sales by CEO Rick E. Winningham. It records one acquisition of 75,000 Ordinary Shares as an award and updates direct and indirect holdings, with no transactions classified as sales or dispositions.

How are the Theravance (TBPH) CEO’s indirect share holdings structured?

The filing lists two indirect positions: 23,400 Ordinary Shares held “As Custodian” and 92,567 Ordinary Shares held “By Trust.” These categories indicate shares associated with the CEO but held through custodial and trust arrangements.